A roundup of some of our favorite 2016 stories on research at Fred Hutch
Dec. 30, 2016
| By Fred Hutch News Service staff
At Fred Hutch News Service, our writers witness daily the excitement of covering new developments in the science of cancer and the human immune system. As 2016 draws to a close, we asked them to sort through the stories about Fred Hutch research they had written this year, and offer our readers a selection of those they felt were most meaningful and important.
Immunotherapy trial results transforming care for rare skin cancer
April 19, 2016
| By Susan Keown / Fred Hutch News Service
With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
Oct. 6, 2015
| By Dr. Rachel Tompa / Fred Hutch News Service
Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.
Keith Winkle will come back to Seattle from Alaska to ride because research saved his life; the Aug. 9-11 bike ride will raise funds to benefit Fred Hutchinson Cancer Research Center
May 24, 2013
| By Justin Matlick
When Keith Winkle was getting radiation treatments at Seattle Cancer Care Alliance, he rode his bike 18 miles from his parents' house to each appointment, then rode all the way back—sometimes with a detour around Lake Washington. It's the kind of commitment to beating cancer—and to cycling—that powers Obliteride, the Aug. 9-11 bike ride to raise funds for Hutchinson Center research. Winkle is training for the event's 100-mile segment.